The Safety and The Efficacy Evaluation of ET-STEM in Patients With Frontotemporal Dementia

Inclusion Criteria:

1. Korean male or female at 40-85 years of age
2. Diagnosis of one of the 3 subtyes of FTD according to the diagnostic criteria for 3subtypes of FTD ① Probable bvFTD (behavior variant FTD) ② svPPA (semantic variant primary progressive aphasia) ③ nfvPPA (nonfluent/agrammatic variant primary progressive aphasia)
3. K-MMSE ≥ 10
4. Subjects with trusted caregivers who regularly contact the subjects and can accompanythe subjects when visiting the hospital.
5. Negative result of amyloid PET imaging
6. A subject who is informed of the clinical trial and signs a consent form (If unable tosign, a consent from a legally acceptable representative is required)

Exclusion Criteria:

1. Subjects with dementia cause by other than FTD (i.e. infection of central nervoussystem, Creutzfeld-Jacob disease, severer head trauma, Huntington's disease,Parkinson's disease, Alzheimer's disease and vascular dementia)
2. Subjects with psychological disorder. (i.e. depression, schizophrenia , bipolardisorder, etc) (except for subjects who were misdiagnosed with psychological diseasedue to the initial neuropsychiatric symptoms of FTD)
3. Subjects with uncontrolled hypotension, hypertension, diabetes and thyroid disease.
4. Subjects with a cancer (including brain tumor)
5. Subjects with bleeding disorder
6. Woman of childbearing age who refused to practice medically acceptable contraceptivemethod (post menopausal patient with no menstruation for at least 12 months isconsidered as infertile)
7. Pregnant or lactating females
8. History of stroke within 3 months prior to study enrollment
9. Substance/alcohol abuse 1
10. Contraindicated for any of the tests performed during the clinical trial period(forexample, MRI, CT,PET)
11. A subject in whom Ommaya reservoir insertion and general anesthesia are considereddifficult
12. Abnormal Laboratory findings at Screening
13. Suspected active lung disease based on chest X-ray at Screening
14. Positive hepatitis B nuclear antibody and hpatitis C antibody
15. Subjects who the principal investigator considers inappropriate for participation inthe study due to the possible harmful effect on the subjects,difficulty in studycompletion, or previous or current medical conditions that may disturb evaluation ofstudy results
16. Subjects who the principal investigator considers impossible to comply with clinicalresearch procedures.